Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Polyclonal Antibody

Anti-Mouse PTK7/CCK-4 Polyclonal Antibody

Catalog #:   PMG47801 Specific References (47) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: ELISA, IHC, WB
Accession: Q8BKG3
Overview

Catalog No.

PMG47801

Species reactivity

Mouse

Host species

Rabbit

Isotype

IgG

Clonality

Polyclonal

Immunogen

E. coli - derived recombinant Mouse PTK7/CCK-4 (Ile24-Ser210).

Tested applications

ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000

Target

Protein-tyrosine kinase 7, Inactive tyrosine-protein kinase 7, CCK4, PTK7, Colon carcinoma kinase 4, Tyrosine-protein kinase-like 7, CCK-4, Pseudo tyrosine kinase receptor 7

Purification

Purified by antigen affinity column.

Accession

Q8BKG3

Applications

ELISA, IHC, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Data Image
  • Western Blot
    Various lysates were subjected to SDS PAGE followed by western blot with PTK7 antibody (PMG47801) at 1 µg/ml.

    Lane 1: A431 cell lysate

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 118 kDa
    Observed MW: 160 kDa
  • Western Blot
    Recombinant Protein lysates were subjected to SDS PAGE followed by western blot with PTK7/CCK-4 antibody (PMG47801) at 1 μg/ml.

    Lane 1: Recombinant protein

    Second Ab: Goat Anti-Rabbit IgG H&L Polyclonal antibody, HRP (PTB96431) at 0.1 μg/mL.

    Predict MW: 23 kDa
    Observed MW: 23 kDa
References

Preclinical Evaluation of PTK7-Targeted Radionuclide Therapy., PMID:40495114

High-Throughput Multiplexed Quantification of Molecules by Aptamer Sequencing (Apt-seq) in Single Cells., PMID:40488675

A phase 1b study of cofetuzumab pelidotin monotherapy in patients with PTK7-expressing recurrent non-small cell lung cancer., PMID:40086026

An overview of Sgc8 aptamer as a potential theranostic agent for cancer with PTK7 oncogenic target., PMID:40033943

Anti-PTK7 Monoclonal Antibodies Suppresses Oncogenic Phenotypes in Cellular and Xenograft Models of Triple-Negative Breast Cancer., PMID:39936972

Therapeutic targeting of the protein tyrosine kinase-7 in cancer: an overview., PMID:39468753

Protein Tyrosine Kinase 7 (PTK7) in Breast Cancer: A Retrospective Analysis of Tumour Expression and Association with Clinical Outcome., PMID:39335176

Fluorescent identification of immunomagnetically captured CTCs using triplex-aptamer-targeted dendritic SiO2@Fe3O4 nanocomposite., PMID:38922365

Recent insights into the therapeutic strategies targeting the pseudokinase PTK7 in cancer., PMID:38773263

Domain-Targeted Membrane Partitioning of Specific Proteins with DNA Nanodevices., PMID:38466380

CAR-Aptamers Enable Traceless Enrichment and Monitoring of CAR-Positive Cells and Overcome Tumor Immune Escape., PMID:38148412

Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates., PMID:37740463

Multiplex Protein Profiling by Low-Signal-Loss Single-Cell Western Blotting with Fluorescent-Quenching Aptamers., PMID:37458448

MTX-13, a Novel PTK7-Directed Antibody-Drug Conjugate with Widened Therapeutic Index Shows Sustained Tumor Regressions for a Broader Spectrum of PTK7-Positive Tumors., PMID:37352387

A novel His-tag-binding aptamer for recombinant protein detection and T cell-based immunotherapy., PMID:37247456

Aptamer-LYTACs for Targeted Degradation of Extracellular and Membrane Proteins., PMID:36722696

Antibody Drug Conjugates in Lung Cancer., PMID:36383905

Anti-PTK7 Monoclonal Antibodies Exhibit Anti-Tumor Activity at the Cellular Level and in Mouse Xenograft Models of Esophageal Squamous Cell Carcinoma., PMID:36293051

Anti-PTK7 Monoclonal Antibodies Inhibit Angiogenesis by Suppressing PTK7 Function., PMID:36139622

Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention., PMID:35977930

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer., PMID:35551360

Dual-Aptamer-Targeted Immunomagnetic Nanoparticles to Accurately Explore the Correlations between Circulating Tumor Cells and Gastric Cancer., PMID:35104098

Antibody drug conjugates in non-small cell lung cancer: An emerging therapeutic approach., PMID:34923203

PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies., PMID:34475869

Immune-related genes and gene sets for predicting the response to anti-programmed death 1 therapy in patients with primary or metastatic non-small cell lung cancer., PMID:34084219

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors., PMID:34083232

Dimeric and Multimeric DNA Aptamers for Highly Effective Protein Recognition., PMID:33182593

PTK7 promotes the malignant properties of cancer stem-like cells in esophageal squamous cell lines., PMID:31894477

A versatile polyion complex can intelligently respond to a tumor microenvironment to eliminate tumor stem cells for enhanced lung cancer targeted therapy., PMID:31355389

Wnt-11 as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer., PMID:31261741

Molecular-Recognition-Based DNA Nanodevices for Enhancing the Direct Visualization and Quantification of Single Vesicles of Tumor Exosomes in Plasma Microsamples., PMID:30644724

Targeting Wnt signaling pseudokinases in hematological cancers., PMID:29989208

Protein tyrosine kinase 7 regulates extracellular matrix integrity and mesenchymal intracellular RAC1 and myosin II activities during Wolffian duct morphogenesis., PMID:29580943

Aptamer-facilitated mass cytometry., PMID:29556738

Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)., PMID:29048660

A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions., PMID:28077676

PTK7 regulates radioresistance through nuclear factor-kappa B in esophageal squamous cell carcinoma., PMID:27557627

Isolation of Human Colon Stem Cells Using Surface Expression of PTK7., PMID:26549850

PTK7 regulates Id1 expression in CD44-high glioma cells., PMID:25204555

PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement., PMID:24409301

TNK2 gene amplification is a novel predictor of a poor prognosis in patients with gastric cancer., PMID:24178904

Bioinspired multivalent DNA network for capture and release of cells., PMID:23150586

A surface energy transfer nanoruler for measuring binding site distances on live cell surfaces., PMID:21038856

Cell-specific internalization study of an aptamer from whole cell selection., PMID:18092308

STAT3-induced WNT5A signaling loop in embryonic stem cells, adult normal tissues, chronic persistent inflammation, rheumatoid arthritis and cancer (Review)., PMID:17203201

Origin and molecular evolution of receptor tyrosine kinases with immunoglobulin-like domains., PMID:16551648

WNT/PCP signaling pathway and human cancer (review)., PMID:16273260

Datasheet
$ 170
Product specifications
50 μg 170 100 μg 280

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Mouse PTK7/CCK-4 Polyclonal Antibody [PMG47801]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only